Schultz and colleagues presented at the 2019 ASH annual meeting the results of a phase I clinical trials of CD19/CD22 bispecific CAR T cells in 19 patients (10 pediatric; 9 adults) with a median age of 23 years (range, 2–68) and median of 4 (range, 2–11) last lines for ALL [58]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.